GUILDFORD, England--(BUSINESS WIRE)--Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery ...

- Company also announced that it raised proceeds of £4,375,000 to fund future commercialization of MED3000 via a warrant exercise by a large institutional shareholder - GUILDFORD, England, June 12, ...

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, is pleased to provide an update on good progress with its ...

Futura Medical has reported phase 3 data on its topical erectile dysfunction treatment MED3000, teeing it up to file for FDA approval of the therapy as an over-the-counter medicine by the end of the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In a confirmatory study, MED3000 was associated with ...